Date Title  
Dec 07, 2020
Summary ToggleSol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo® for the Treatment of Acne Vulgaris
 
Nov 12, 2020
Summary ToggleSol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update
 
Nov 09, 2020
Summary ToggleSol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020
 
Nov 04, 2020
Summary ToggleSol-Gel Technologies to Report Third Quarter 2020 Financial Results on November 12, 2020
 
Sep 10, 2020
Summary ToggleSol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Epsolay® for the Treatment of Inflammatory Lesions of Rosacea
 
Sep 08, 2020
Summary ToggleSol-Gel to Present at Upcoming Healthcare Investor Conferences in September
 
Sep 03, 2020
Summary ToggleSol-Gel Technologies Collaboration Partner Filed First-to-File Paragraph IV Certification for Duobrii®
 
Aug 06, 2020
Summary ToggleSol-Gel Technologies Reports Second Quarter 2020 Financial Results and Corporate Update
 
Jul 29, 2020
Summary ToggleSol-Gel Technologies to Report Second Quarter 2020 Financial Results on August 6, 2020
 
Jul 28, 2020
Summary ToggleSol-Gel Technologies Partnered Generic Product Expected to Launch in the Second Quarter of 2021
 
Displaying 11 - 20 of 72 results